Aachen, 18 February 2013 – Today, the Grünenthal Group announced the appointment of Oscar Ferenczi to Executive Vice President for the SBU Grünenthal Latin America with immediate effect. In his responsibility he will also take over the task of General Manager Grünenthal S.A. Panama, the regional head office of the company in Latin America, as well as General Manger Grünenthal Latin America, Miami. As a member of the Group Operating Committee of the pain specialist headquartered in Aachen (Germany), Oscar Ferenczi will be based in Miami, Florida, and will report directly to Grünenthal Group Chief Executive Officer, Harald F. Stock, Ph.D.
“Strengthening our businesses in Latin America is one of our core strategic objectives as we are aiming to generate 40 percent of Grünenthal’s commercial business from the region in 2015. I am glad that Oscar has decided to lead the Group’s Strategic Business Unit with its ambitious, dedicated, and passionate people. He joins Grünenthal with a successful track record in general management, marketing, sales and finance in both the generics and patented segments of the pharmaceutical industry”, commented Harald F. Stock, Ph.D., CEO of the Grünenthal Group.
Oscar Ferenczi, Executive Vice President SBU LATAM, is looking forward to his new position at Grünenthal: “I am excited about joining Grünenthal and the opportunity to lead the team into a driving force in Latin America. Given the potential of the region and the opportunities that exist, I see Grünenthal’s strategic plans as the basis for its overall success and positioning in the region.”
Excellent position for further growth – both organic and external
In Latin America, Grünenthal is further strengthening the business in these fast-growth emerging markets with selected acquisitions and licensing deals. Following the successful acquisition and integration of the Brazilian company Selfarma in 2011, Grünenthal announced in June 2012 an exclusive agreement with US-based Horizon Pharma for the commercialization of DUEXIS® in Latin America. The company’s current leading market position in Latin America is mainly based on a strong portfolio in pain, Grünenthal’s global core competence along with strong regional products.
Additional information for editorial offices:
Oscar Ferenczi’s CV can be downloaded on our Website.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation.
Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 26 percent of revenues in 2012. Grünenthal’s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.
Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries. Today, approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of €973 mn.
More information: www.grunenthal.com.